ANIX — Anixa Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $98.80m
- $82.42m
- 22
- 13
- 80
- 32
Annual cashflow statement for Anixa Biosciences, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.1 | -13.8 | -9.93 | -12.7 | -11 |
| Non-Cash Items | 8.11 | 6.79 | 4.78 | 4.84 | 3.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.079 | 0.485 | -1.06 | 0.526 | 0.152 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -4.94 | -6.49 | -6.21 | -7.33 | -7.17 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -3.92 | -10.7 | -5.6 | 4.28 | 4.87 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.92 | -10.7 | -5.6 | 4.28 | 4.87 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 31.6 | 0.452 | 0.366 | 3.42 | 2.28 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.7 | -16.8 | -11.4 | 0.356 | -0.027 |